Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications

References

• Burnstock G. Discovery of purinergic signalling, the initial resistance and current explosion of interest. Br J Pharmacol. 2012;167:238–255.
   PubMed Web of Science ®Google Scholar
• Chen CC, Akopian AN, Sivilotti L, et al. A P2X purinoceptor expressed by a subset of sensory neurons. Nature. 1995;377:428–431.
   PubMed Web of Science ®Google Scholar
• Lewis C, Neidhart S, Holy C, et al. Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature. 1995;377:432–435.
   PubMed Web of Science ®Google Scholar
• North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002;82:1013–1067.
   PubMed Web of Science ®Google Scholar
• Motoyuki H, Eric G. Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature. 2012;485:207–212.
   PubMed Web of Science ®Google Scholar
• Aschrafi A, Sadtler S, Niculescu C, et al. Trimeric architecture of homotrimeric P2X2 and heteromeric P2X1+2 receptor subtypes. J Mol Biol. 2004;342:333–343.
   PubMed Web of Science ®Google Scholar
• Valera S, Hussy N, Evans RJ, et al. A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP. Nature. 1994;371:516–519.
   PubMed Web of Science ®Google Scholar
• Browne LE, Jiang LH, North RA. New structure enlivens interest in P2X receptors. Trends Pharmacol Sci. 2010;31(5):229–237.
   PubMed Web of Science ®Google Scholar
• Dal Ben D, Buccioni M, Lambertucci C, et al. Purinergic P2X receptors: structural models and analysis of ligand-target interaction. Eur J Med Chem. 2015;7(89):561–580.
   Google Scholar
• Mansoor SE, Lu W, Oosterheert W, et al. X-ray structures define human P2X3 receptor gating cycle and antagonist action. Nature. 2016;538:66−71.
   PubMed Web of Science ®Google Scholar
• Jarvis MF. Contributions of P2X3 homotrimeric and heteromeric channels to acute and chronic pain. Expert Opin Ther Targets. 2003;7:513–522.
   PubMed Web of Science ®Google Scholar
• Honore P, Kage K, Mikusa J, et al. Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain. 2002;99:11–19.
   PubMed Web of Science ®Google Scholar
• Dorn G, Patel S, Wotherspoon G, et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 2004;32:e49.
   PubMed Web of Science ®Google Scholar
• Hamilton SG, Wade A, McMahon SB. The effects of inflammation and inflammatory mediators on nociceptive behavior induced by ATP analogues in the rat. Br J Pharmacol. 1999;126:326–332.
   PubMed Web of Science ®Google Scholar
• Cook SP, McCleskey EW. Cell damage excites nociceptors through release of cytosolic ATP. Pain. 2002;95:41–47.
   PubMed Web of Science ®Google Scholar
• Gu JG, MacDermott AB. Activation of ATP P2X receptors elicits glutamate release from sensory neuron synapses. Nature. 1997;389:749–753.
   PubMed Web of Science ®Google Scholar
• Gu JG. P2X receptor-mediated modulation of sensory transmission to the spinal cord dorsal horn. Neuroscientist. 2003;9:370–378.
   PubMed Web of Science ®Google Scholar
• Xu GY, Huang LY. Peripheral inflammation sensitizes P2X receptor-mediated responses in rat dorsal root ganglion neurons. J Neurosci. 2002;22:93–102.
   PubMed Web of Science ®Google Scholar
• Cockayne DA, Hamilton SG, Zhu Q-M, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000;407:1011–1015.
   PubMed Web of Science ®Google Scholar
• Souslova V, Cesare P, Ding Y, et al. Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature. 2000;407:1015–1017.
   PubMed Web of Science ®Google Scholar
• Fabbretti E. ATP P2X3 receptors and neuronal sensitization. Front Cell Neurosci. 2013;7:236.
   PubMed Web of Science ®Google Scholar
• Fabbretti E, D’Arco M, Fabbro A, et al. Delayed upregulation of ATP P2X3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide. J Neurosci. 2006;26(23):6163–6171.
   PubMed Web of Science ®Google Scholar
• Müller CE. Emerging structures and ligands for P2X3 and P2X4 receptors towards novel treatments of neuropathic pain. Purinergic Signal. 2010;6(2):145–148.
   PubMedGoogle Scholar
• Rapp DE, Wood NL, Bassignani M, et al. Clinical variables and stone detection in patients with flank pain. Can J Urol. 2016;23(5):8441–8445.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Banning AS, Cockayne DA, et al. Bladder and cutaneous sensory neurons of the rat express different functional P2X receptors. Neurosci. 2003;120:667–675.
   PubMed Web of Science ®Google Scholar
• Shinoda M, Feng B, Gebhart GF. Peripheral and central P2X3 receptor contributions to colon mechanosensitivity and hypersensitivity in the mouse. Gastroenterology. 2009;137(6):2096–2104.
   PubMed Web of Science ®Google Scholar
• Bian X, Ren J, DeVries M, et al. Peristalsis is impaired in the small intestine of mice lacking the P2X3 subunit. J Physiol. 2003;15(551):309–322.
   Google Scholar
• Brouns I, Pintelon I, De Proost, et al. Neurochemical characterization of sensory receptors in airway smooth muscle: comparison with pulmonary neuroepithelial bodies. Histochem Cell Biol. 2006;125(4):351–367.
   PubMed Web of Science ®Google Scholar
• Deiteren A, van der Linden L, de Wit A, et al. P2X3 receptors mediate visceral hypersensitivity during acute chemically-induced colitis and in the post-inflammatory phase via different mechanisms of sensitization. PLoS One. 2015;10(4):e0123810.
   PubMed Web of Science ®Google Scholar
• Mason HS, Bourke S, Kemp PJ. Selective modulation of ligand-gated P2X purinoceptor channels by acute hypoxia is mediated by reactive oxygen species. Mol Pharmacol. 2004;66:1525–1535.
   PubMed Web of Science ®Google Scholar
• Volpini R, Mishra RC, Kachare DD, et al. Adenine-based acyclic nucleotides as novel P2X3 receptor ligands. J Med Chem. 2009 13;52(15):4596–4603.
   PubMed Web of Science ®Google Scholar
• Dal Ben D, Marchenkova A, Thomas A, et al. 2ʹ,3ʹ-O-substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents. Purinergic Signal. 2017;13(1):61–74.
   PubMed Web of Science ®Google Scholar
• Dal Ben D, Adinolfi E. Purinergic P2X receptors: physiological and pathological roles and potential as therapeutic targets. Curr Med Chem. 2015;22(7):782.
   PubMed Web of Science ®Google Scholar
• Dal Ben D, Buccioni M, Lambertucci C, et al. Investigation on 2ʹ,3ʹ-O-substituted ATP derivatives and analogs as novel P2X3 receptor antagonists. ACS Med Chem Lett. 2019 26;10(4):493–498.
   PubMed Web of Science ®Google Scholar
• North RA, Jarvis MF. P2X receptors as drug targets. Mol Pharmacol. 2013;83(4):759–769.
   PubMed Web of Science ®Google Scholar
• Jarvis MF, Burgard EC, McGaraughty S. et al. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci USA. 2002;99(26):17179–17184.
   PubMed Web of Science ®Google Scholar
• Gever JR, Cockayne DA, Dillon MP, et al. Pharmacology of P2X channels. Pflugers Arch. 2006;452:513–537.
   PubMed Web of Science ®Google Scholar
• Carter DS, Alam M, Cai H, et al. Identification and SAR of novel diaminopyrimidines. Part 1: the discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. Bioorg Med Chem Lett. 2009;19:1628–1631.
   PubMed Web of Science ®Google Scholar
• Gever JR, Soto R, Henningsen RA, et al. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol. 2010;160:1387–1398.
   PubMed Web of Science ®Google Scholar
• Ballini E, Virginio C, Medhurst SJ, et al. Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors with in vivo efficacy in a pain model. Br J Pharmacol. 2011;163:1315–1325.
   PubMed Web of Science ®Google Scholar
• Lambertucci C, Sundukova M, Kachare DD, et al. Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists. Eur J Med Chem. 2013;65:41–50.
   PubMed Web of Science ®Google Scholar
• Lambertucci C, Dal Ben D, Buccioni M, et al. Medicinal chemistry of P2X receptors: agonists and orthosteric antagonists. Curr Med Chem. 2015;22:915–928.
   PubMed Web of Science ®Google Scholar
• Bölcskei H, Farkas B. P2X3 and P2X2/3 receptor antagonists. Pharm Pat Anal. 2014;3(1):53–64.
   PubMedGoogle Scholar
• Joel DR, Gever R, Ford AP, et al. Action of MK‐7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitization. Br J Pharmacol. 2019;176:2279–2291.
   PubMed Web of Science ®Google Scholar
• Szántó G, Makó A, Bata I, et al. New P2X3 receptor antagonists. Part 1: discovery and optimization of tricyclic compounds. Bioorg Med Chem Lett. 2016;26(16):3896–3904.
   PubMed Web of Science ®Google Scholar
• Szántó G, Makó A, Vágó I, et al. New P2X3 receptor antagonists. Part 2: identification and SAR of quinazolinones. Bioorg Med Chem Lett. 2016;26(16):3905–3912.
   PubMed Web of Science ®Google Scholar
• Roche Palo Alto. Triazole-substituted arylamides as P2X3 and P2X2/3 modulators. US 2015/0065521 Al. 2015.
   Google Scholar
• Dillon MP, Hawley RC, Chen L, et al. Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists. US 2015/0191487 A. 2015.
   Google Scholar
• Roche Palo Alto. Indole, indazole and benzimidazole arylamides as P2X3 and P2X2/3 antagonists. US 2016/0362395 Al. 2016.
   Google Scholar
• Roche Palo Alto. Biphenyl and phenyl-pyridine amides as P2X3 and P2X2/3 antagonists. US 2017/0057932 Al. 2017.
   Google Scholar
• Roche Palo Alto. Substituted pyridine as P2X3 and P2X2/3 antagonists. US 2017/0056398 Al. 2017.
   Google Scholar
• Roche Palo Alto. Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists. US 2017/0081320 Al (201). 2017.
   Google Scholar
• Roche Palo Alto. Pyrazole substituted arylamides as P2X3 and P2X2/3 antagonists. US 2017/0096416 Al. 2017.
   Google Scholar
• Roche Palo Alto. Thiazole, and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists. US 2017/0182057 Al. 2017.
   Google Scholar
• Roche Palo Alto. Diaminopyrimidines as P2X3 and P2X2/3 antagonists. EP 2 343 282 B1. 2015.
   Google Scholar
• Roche Palo Alto. Diaminopyrimidines as P2X3 and P2X2/3 antagonists. US 2005/7,858, 632. 2005.
   Google Scholar
• Roche Palo Alto. Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases. US 2018/0311240 Al. 2018.
   Google Scholar
• Roche Palo Alto. Diaminopyrimidines P2X3 and P2X2/3 antagonists. US 2019/0016688 Al. 2019.
   Google Scholar
• Anthony PF, Undem BJ. The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Front Cell Neurosci. 2013;7:267.
   PubMed Web of Science ®Google Scholar
• Afferent pharmaceuticals methods and compositions for treating diseases and conditions WO 2016/004358 Al. 2016.
   Google Scholar
• Ibrahim P, Hawley RC, Ford A, et al. Afferent pharmaceuticals. Crystalline salts and polymorphs of a P2X3 antagonist. WO 2018/118668 Al. 2018.
   Google Scholar
• Abdulqawi R, Dockry R, Holt K, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2015;385(9974):1198–1205.
   PubMed Web of Science ®Google Scholar
• Roe NA, Lundy FT, Litherland GJ, et al. Therapeutic targets for the treatment of chronic cough. Curr Otorhinolaryngol Rep. 2019;7(2):116–128.
   Google Scholar
• Afferent Pharmaceuticals. Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough. WO 2017/058645 Al. 2017.
   Google Scholar
• Ford AP, Glaub KS, Kitt MM, et al. Afferent pharmaceuticals. Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough. US 2018/02800388 A1. 2018.
   Google Scholar
• Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain. EP 2 860 178 A2. 2015.
   Google Scholar
• Patara Pharma, LLC combination therapies for the treatment of lung diseases. WO 2017/011729 Al. 2017.
   Google Scholar
• Asana Biosciences. P2X3 and/or P2X2; compounds and methods. US 2018/0186793 Al. 2018.
   Google Scholar
• Gwangju Institute of Science and Technology. Novel 5-hydroxy pyridine-based compound for use as p2xl and p2x3 receptor antagonist and pharmaceutical composition comprising same. WO 2018/169286 Al. 2018.
   Google Scholar
• Young-Hwan J, Ok K Y, Hai L, et al. Discovery of potent antiallodynic agents for neuropathic pain targeting P2X3 receptors. ACS Chem Neurosci. 2017;8:1465−78.
   PubMed Web of Science ®Google Scholar
• Asana Biosciences. P2X3 and/or P2X2/3; compounds and methods. WO 2018/064135. 2018.
   Google Scholar
• Bellus Health Cough INC. Selective P2X3 modulators US 10,111,883 B1. 2018.
   Google Scholar
• Bellus Health Cough INC. Selective P2X3 modulators. WO 2019/064079 A2. 2019.
   Google Scholar
• Burnstock G. A basis for distinguishing two types of purinergic receptor. In: Straub RW, Bolis L, editors. Cell membrane receptors for drugs and hormones: a multidisciplinary approach. New York: Raven Press; 1978. p. 107–118.
   Google Scholar
• Burnstock G. A unifying purinergic hypothesis for the initiation of pain. Lancet. 1996;347:1604–1605.
   PubMed Web of Science ®Google Scholar
• Kawate T, Carlisle Michel J, Birdsong WT, et al. Crystal structure of the ATP-gated P2X4 ion channel in the closed state. Nature. 2009;460:592–598.
   PubMed Web of Science ®Google Scholar